Investigation into drug release from colon-specific azoreductase-activated steroid prodrugs using in-vitro models

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 6, 2011, Pages 806-816

  Ruiz, Juan F Marquez ^a   Kedziora, Kinga ^a   Windle, Henry ^a   Kelleher, Dermot P ^a   Gilmer, John F ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

azoreductase; colon; cyclization; prodrug; steroid

Indexed keywords

AZO REDUCTASE; OPN 501; ORGANIC SOLVENT; PHENYLACETIC ACID; PHENYLPROPIONIC ACID DERIVATIVE; PREDNISOLONE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; BACTEROIDES FRAGILIS; CELL DENSITY; CHEMICAL REACTION; CLOSTRIDIUM PERFRINGENS; COLON FLORA; CONTROLLED STUDY; CYCLIZATION; DRUG RELEASE; DRUG STRUCTURE; ENZYME ACTIVATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; IN VITRO STUDY; IONIC STRENGTH; LACTAMIZATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PH; REDUCTION; SOLVENT EXTRACTION;

AMINO ACIDS; ANIMALS; COLON; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; INFLAMMATORY BOWEL DISEASES; MICE; MICE, INBRED BALB C; NADH, NADPH OXIDOREDUCTASES; PREDNISOLONE; PRODRUGS;

EID: 79956189034     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01289.x     Document Type: Article

References (30)

1. Cohen RD, et al,. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263-1276. (Pubitemid 30263523)
2. Campieri M,. New steroids and new salicylates in inflammatory bowel disease. Gut 2002; 50: iii43-iii46. (Pubitemid 34413562)
3. Basit AW,. Oral colon-specific drug delivery using amylose-based film coatings. Pharm Technol Eur 2000; 12: 30-36.
4. Haeberlin B, et al,. In vitro evaluation of dexamethasone-beta-D- glucuronide for colon-specific drug delivery. Pharm Res 1993; 11: 1553-1562. (Pubitemid 23325656)
5. Hu Z, et al,. New preparation method of intestinal pressure-controlled colon delivery capsules coating machine and evaluation in beagle dogs. J Controlled Release 1998; 56: 293-302. (Pubitemid 28511149)
6. Jung YJ, et al,. Prednisolone 21-sulfate sodium: a colon-specific pro-drug of prednisolone. J Pharm Pharmacol 2003; 55: 1075-1082. (Pubitemid 36998647)
7. Yano H, et al,. Colon specific delivery of prednisolone-appended α-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J Controlled Release 2002; 79: 103-112. (Pubitemid 34164164)
8. Sinha VR, Kumria R,. Colonic drug delivery: prodrug approach. Pharm Res 2001; 18: 557-564. (Pubitemid 32595781)
9. Wiggins JB, Rajapakse R,. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol 2009; 5: 1279-1284.
10. Jain A, et al,. Azo chemistry and its potential for colonic delivery. Crit Rev Ther Drug Carrier Syst 2006; 23: 349-400.
11. Carceller E, et al,. Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. J Med Chem 2001; 44: 3001-3013. (Pubitemid 32884153)
12. Márquez Ruiz JF, et al,. Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease. J Med Chem 2009; 59: 3205-3211.
13. Gomes P, et al,. Cyclization-activated prodrugs. Molecules 2007; 12: 2484-2506.
14. Temple NJ, El-Khatib SM,. High-fat diets and fecal level of reductase and colon mucosal level of ornithine decarboxylase, beta-glucuronidase, 5′-nucleotidase, ATPase, and esterase in mice. J Natl Cancer Inst 1984; 72: 679-684. (Pubitemid 14161167)
15. Berry LM, et al,. Esterase activities in the blood, liver and intestine of several preclinical species and humans. Drug Metab Lett 2009; 3: 70-77.
16. Khan AA, et al,. Identification of predominant human and animal anaerobic intestinal bacterial species by terminal restriction fragment patterns (TRFPs): a rapid, PCR-based method. Mol Cell Probes 2001; 15: 349-355. (Pubitemid 34188286)
17. Rafii F, Cerniglia CE,. Comparison of the azoreductase and nitroreductase from Clostridium perfringens. Appl Environ Microbiol 1993; 59: 1731-1734. (Pubitemid 23171541)
18. Rafii F, Cerniglia CE,. Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Environ Health Perspect 1995; 103: 17-19.
19. Rafii F, Coleman T,. Cloning and expression in Escherichia coli of an azoreductase gene from Clostridium perfringens and comparison with azoreductase genes from other bacteria. J Basic Microbiol 1999; 39: 29-35. (Pubitemid 29092110)
20. Rafii F, et al,. Azoreductase activity of anaerobic bacteria isolated from human intestinal microflora. Appl Environ Microbiol 1990; 56: 2146-2151. (Pubitemid 20218592)
21. Semdé R, et al,. Study of important factors involved in azo derivative reduction by Clostridium Perfringens. Int J Pharm 1998; 161: 45-54. (Pubitemid 28080658)
22. Fife TH, Duddy NW,. Intramolecular aminolysis of esters. Cyclization of esters of (o-Aminophenyl)acetic acid. J Am Chem Soc 1983; 105: 74-79.
23. Kirby AJ, Mujahid TG,. Anilide formation from an aliphatic ester. The mechanism of cyclisation of methyl 3-(2-aminophenyl)propionate. J Chem Soc Perkin Trans 1979; 2: 1610-1616.
24. Satterthwait AC, Jencks WP,. The mechanism of the aminolysis of acetate esters. J Am Chem Soc 1974; 96: 7018-7031.
25. Evans DF, et al,. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988; 29: 1035-1041.
26. Fallingborg J, et al,. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci 1993; 38: 1989-1993. (Pubitemid 23336560)
27. Nugent S, et al,. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001; 48: 571-577. (Pubitemid 32234805)
28. Stippler E, et al,. Comparison of US pharmacopeia simulated intestinal fluid TS (without pancreatin) and phosphate standard buffer pH 6.8, TS of the international pharmacopoeia with respect to their use in in vitro dissolution testing. Dissolution Technol 2004; 11: 6-10.
29. Diakidou A, et al,. Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm Res 2009; 26: 2141-2151.
30. Schiller C, et al,. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2005; 22: 971-979. (Pubitemid 41634879)